Suppr超能文献

使用循环死亡供体进行肝肾联合移植可改善国家结果。

Improved National Results With Simultaneous Liver-Kidney Transplantation Using Donation After Circulatory Death Donors.

机构信息

Department of Transplant, Mayo Clinic Florida, Jacksonville, FL.

出版信息

Liver Transpl. 2020 Mar;26(3):397-407. doi: 10.1002/lt.25653. Epub 2020 Feb 3.

Abstract

Previous large registry studies have demonstrated inferior outcomes for simultaneous liver-kidney transplantation (SLKT) recipients of grafts from donation after circulatory death (DCD) donors compared with those from donation after brain death (DBD) donors in the era from 2000 to 2010. Given the improving national results in liver transplantation alone using grafts from DCD donors, the present study aimed to investigate if results with DCD-SLKT have improved in the modern era. Patients undergoing SLKT between 2000 and 2018 were obtained from the United Network for Organ Sharing Standard Analysis and Research file and divided into 2 eras based on the date of SLKT: era 1 (2000-2010) and era 2 (2011-2018). Improvement in DCD-SLKT patient, liver graft, and kidney graft survival rates was seen between era 1 and era 2 (P < 0.001). Concurrently, there was a decrease in the proportion of critically ill (P = 0.02) and retransplant (P = 0.006) candidates undergoing DCD-SLKT. When DCD-SLKT in era 2 was compared with a propensity-matched cohort of DBD-SLKT in era 2, no differences in patient (P = 0.99), liver graft (P = 0.19), or kidney graft (P = 0.90) survival were observed. In addition, both bilirubin (0.5 versus 0.5 mg/dL; P = 0.86) and creatinine (1.2 versus 1.2 mg/dL; P = 0.68) at last follow-up were not different between the DCD-SLKT and DBD-SLKT patients in era 2. In conclusion, in the most recent era, patients undergoing DCD-SLKT were able to achieve similar outcomes compared with matched patients undergoing DBD-SLKT. DCD-SLKT represents a viable option for appropriately selected recipients.

摘要

先前的大型登记研究表明,与脑死亡(DBD)供体来源的器官相比,2000 年至 2010 年期间,接受循环死亡(DCD)供体来源的肝肾联合移植(SLKT)的受者结局较差。鉴于单独使用 DCD 供体的肝移植在全国范围内的结果不断改善,本研究旨在探讨在现代时代,DCD-SLKT 的结果是否有所改善。从器官共享联合网络标准分析和研究文件中获得了 2000 年至 2018 年间接受 SLKT 的患者,并根据 SLKT 的日期将其分为 2 个时期:时期 1(2000-2010 年)和时期 2(2011-2018 年)。与时期 1 相比,时期 1 和时期 2 均观察到 DCD-SLKT 患者、肝移植物和肾移植物存活率的改善(P < 0.001)。同时,进行 DCD-SLKT 的危重病(P = 0.02)和再次移植(P = 0.006)患者的比例有所下降。当将时期 2 的 DCD-SLKT 与时期 2 的匹配倾向 DBD-SLKT 队列进行比较时,在患者(P = 0.99)、肝移植物(P = 0.19)或肾移植物(P = 0.90)存活率方面均无差异。此外,在时期 2 中,DCD-SLKT 和 DBD-SLKT 患者的最后随访时胆红素(0.5 与 0.5 mg/dL;P = 0.86)和肌酐(1.2 与 1.2 mg/dL;P = 0.68)均无差异。总之,在最近的一个时期,接受 DCD-SLKT 的患者与接受匹配的 DBD-SLKT 的患者相比,能够获得相似的结果。DCD-SLKT 是一种为适当选择的受者提供的可行选择。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验